Close Menu

NEW YORK (GenomeWeb) – Illumina has struck a deal with Harvard Pilgrim Health Care to provide noninvasive prenatal testing to women with average-risk pregnancies. The nonprofit health services company covers around 1.2 million people in Massachusetts, Connecticut, New Hampshire, and Maine.

Under the terms of the value-based contract, Harvard Pilgrim will cover NIPT for average-risk pregnancies. However, if one-year costs of testing exceed a pre-established baseline, Illumina will reimburse Harvard Pilgrim for the costs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.